. "Radafaxine (developmental code name GW-353,162), also known as (2S,3S)-hydroxybupropion or (S,S)-hydroxybupropion, is a norepinephrine\u2013dopamine reuptake inhibitor (NDRI) which was under development by GlaxoSmithKline in the 2000s for a variety of different indications but was never marketed. These uses included treatment of restless legs syndrome, major depressive disorder, bipolar disorder, neuropathic pain, fibromyalgia, and obesity. Regulatory filing was planned for 2007, but development was discontinued in 2006 due to \"poor test results\"."@en . . . "106083"^^ . . "Clc1cccc[C@]2OCCC"@en . . "--2--3,5,5-trimethylmorpholin-2-ol"@en . "9795056" . "464379587"^^ . "1172928"^^ . . . "Radafaxin ist ein selektiver Noradrenalin-Dopamin-Wiederaufnahmehemmer (NDRI), der von GlaxoSmithKline urspr\u00FCnglich zur Behandlung des Restless-Legs-Syndroms entwickelt wurde. Allerdings wurde die Entwicklung 2006 wegen schlechter Testergebnisse eingestellt."@de . . . . . . . . . . "Radafaxin"@de . . . "none"@en . "SYD411HZ3S" . "13"^^ . . "7970823"^^ . . . . "-Hydroxybupropion; -Hydroxybupropion; GW-353,162"@en . "1"^^ . . . . . . "7657"^^ . "192374"^^ . . . . "\u0631\u0627\u062F\u0627\u0641\u0643\u0633\u064A\u0646 \u0623\u0648\u0631\u0627\u062F\u0627\u0641\u0643\u0633\u064A\u0646(\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Radafaxine)\u200F \u0647\u0648 \u062F\u0648\u0627\u0621 \u0645\u0647\u062F\u0626 [GW-353\u060C 162] \u0635\u0646\u0639\u062A\u0647 \u0634\u0631\u0643\u0629 \u062C\u0644\u0627\u0643\u0633\u0648 \u0633\u0645\u064A\u062B \u0643\u0644\u0627\u064A\u0646\u060C \u0643\u0627\u0646 \u064A\u0633\u062A\u062E\u062F\u0645 \u0643\u0645\u0636\u0627\u062F \u0644\u0644\u0627\u0643\u062A\u0626\u0627\u0628\u060C \u0648\u0644\u0643\u0646 \u0634\u0631\u0643\u0629 \u062C\u0644\u0627\u0643\u0633\u0648 \u0633\u0645\u064A\u062B \u0643\u0644\u0627\u064A\u0646 \u0623\u0648\u0642\u0641\u062A \u062A\u0635\u0646\u064A\u0639\u0647 \u0641\u064A \u0639\u0627\u0645 2006 \u0648\u0633\u062D\u0628\u062A\u0647 \u0645\u0646 \u0627\u0644\u0623\u0633\u0648\u0627\u0642 \u0641\u064A \u0639\u0627\u0645 2007\u060C \u0628\u0633\u0628\u0628 \u0646\u062A\u0627\u0626\u062C \u062A\u0623\u062B\u064A\u0631\u0627\u062A\u0647 \u0643\u0627\u0646\u062A \u0636\u0626\u064A\u0644\u0629 \u0639\u0644\u0649 \u0627\u0644\u0645\u0631\u0636\u0649."@ar . . "106083-71-0" . "1110493210"^^ . "changed"@en . . "Radafaxine"@en . . "changed"@en . . . "9795056"^^ . "HCl"@en . . . . . . "192374-14-4" . . "Radafaxin ist ein selektiver Noradrenalin-Dopamin-Wiederaufnahmehemmer (NDRI), der von GlaxoSmithKline urspr\u00FCnglich zur Behandlung des Restless-Legs-Syndroms entwickelt wurde. Allerdings wurde die Entwicklung 2006 wegen schlechter Testergebnisse eingestellt."@de . . . . "Q47741214K" . . . . "1"^^ . . . . . "\u0631\u0627\u062F\u0627\u0641\u0643\u0633\u064A\u0646 \u0623\u0648\u0631\u0627\u062F\u0627\u0641\u0643\u0633\u064A\u0646(\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Radafaxine)\u200F \u0647\u0648 \u062F\u0648\u0627\u0621 \u0645\u0647\u062F\u0626 [GW-353\u060C 162] \u0635\u0646\u0639\u062A\u0647 \u0634\u0631\u0643\u0629 \u062C\u0644\u0627\u0643\u0633\u0648 \u0633\u0645\u064A\u062B \u0643\u0644\u0627\u064A\u0646\u060C \u0643\u0627\u0646 \u064A\u0633\u062A\u062E\u062F\u0645 \u0643\u0645\u0636\u0627\u062F \u0644\u0644\u0627\u0643\u062A\u0626\u0627\u0628\u060C \u0648\u0644\u0643\u0646 \u0634\u0631\u0643\u0629 \u062C\u0644\u0627\u0643\u0633\u0648 \u0633\u0645\u064A\u062B \u0643\u0644\u0627\u064A\u0646 \u0623\u0648\u0642\u0641\u062A \u062A\u0635\u0646\u064A\u0639\u0647 \u0641\u064A \u0639\u0627\u0645 2006 \u0648\u0633\u062D\u0628\u062A\u0647 \u0645\u0646 \u0627\u0644\u0623\u0633\u0648\u0627\u0642 \u0641\u064A \u0639\u0627\u0645 2007\u060C \u0628\u0633\u0628\u0628 \u0646\u062A\u0627\u0626\u062C \u062A\u0623\u062B\u064A\u0631\u0627\u062A\u0647 \u0643\u0627\u0646\u062A \u0636\u0626\u064A\u0644\u0629 \u0639\u0644\u0649 \u0627\u0644\u0645\u0631\u0636\u0649."@ar . "1"^^ . . . . . "RCOBKSKAZMVBHT-TVQRCGJNSA-N"@en . . . . . . . . "SYD411HZ3S"@en . . "Radafaxine (developmental code name GW-353,162), also known as (2S,3S)-hydroxybupropion or (S,S)-hydroxybupropion, is a norepinephrine\u2013dopamine reuptake inhibitor (NDRI) which was under development by GlaxoSmithKline in the 2000s for a variety of different indications but was never marketed. These uses included treatment of restless legs syndrome, major depressive disorder, bipolar disorder, neuropathic pain, fibromyalgia, and obesity. Regulatory filing was planned for 2007, but development was discontinued in 2006 due to \"poor test results\"."@en . . "Q47741214K"@en . . . . . . . . "2"^^ . . . . . "9387442"^^ . . . . . . "\u0631\u0627\u062F\u0627\u0641\u0643\u0633\u064A\u0646"@ar . . "1172928" . . "225"^^ . . "18"^^ . . . .